Literature DB >> 27456058

New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.

Anja M Schmitt1, Ilaria Marinoni2, Annika Blank2, Aurel Perren2.   

Abstract

The recent findings on the roles of death-associated protein 6/α-thalassemia/mental retardation X-linked (DAXX/ATRX) in the development of pancreatic neuroendocrine tumors (PanNETs) have led to major advances in the molecular understanding of these rare tumors and open up completely new therapeutic windows. This overview aims at giving a simplified view on these findings and their possible therapeutic implications. The importance of epigenetic changes in PanNET is also underlined by recent findings of a cross-species study on microRNA (miRNA) and messenger RNA (mRNA) profiles in PanNETs.

Entities:  

Keywords:  Alternative lengthening of telomeres; DAXX/ATRX; Epigenetics; Methylation; Pancreatic neuroendocrine tumor; Review

Mesh：

Substances：

Year:  2016        PMID： 27456058     DOI： 10.1007/s12022-016-9447-2

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN： 1046-3976            Impact factor:   3.943


  18 in total

1.  Genomic imbalances in the progression of endocrine pancreatic tumors.

Authors:  J Zhao; H Moch; A F Scheidweiler; A Baer; A A Schäffer; E J Speel; J Roth; P U Heitz; P Komminoth
Journal:  Genes Chromosomes Cancer       Date:  2001-12       Impact factor: 5.006

Review 2.  Epigenetic therapy for solid tumors: from bench science to clinical trials.

Authors:  Yen-Yi Juo; Xue-Jun Gong; Ankita Mishra; Xiao Cui; Stephen B Baylin; Nilofer S Azad; Nita Ahuja
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

3.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

4.  Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Authors:  Rachel Litman Flynn; Kelli E Cox; Maya Jeitany; Hiroaki Wakimoto; Alysia R Bryll; Neil J Ganem; Francesca Bersani; Jose R Pineda; Mario L Suvà; Cyril H Benes; Daniel A Haber; Francois D Boussin; Lee Zou
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

5.  Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor.

Authors:  Martin Anlauf; Tetsuji Enosawa; Tobias Henopp; Anja Schmitt; Oliver Gimm; Michael Brauckhoff; Henning Dralle; Anette Musil; Steffen Hauptmann; Aurel Perren; Günter Klöppel
Journal:  Am J Surg Pathol       Date:  2008-07       Impact factor: 6.394

6.  Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.

Authors:  Michele Stefanoli; Stefano La Rosa; Nora Sahnane; Chiara Romualdi; Roberta Pastorino; Alessandro Marando; Carlo Capella; Fausto Sessa; Daniela Furlan
Journal:  Neuroendocrinology       Date:  2014-07-05       Impact factor: 4.914

Review 7.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 8.  Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.

Authors:  C A Zahnow; M Topper; M Stone; T Murray-Stewart; H Li; S B Baylin; R A Casero
Journal:  Adv Cancer Res       Date:  2016-03-02       Impact factor: 6.242

9.  A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.

Authors:  Anguraj Sadanandam; Stephan Wullschleger; Costas A Lyssiotis; Carsten Grötzinger; Stefano Barbi; Samantha Bersani; Jan Körner; Ismael Wafy; Andrea Mafficini; Rita T Lawlor; Michele Simbolo; John M Asara; Hendrik Bläker; Lewis C Cantley; Bertram Wiedenmann; Aldo Scarpa; Douglas Hanahan
Journal:  Cancer Discov       Date:  2015-10-07       Impact factor: 39.397

10.  Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

Authors:  Roeland F de Wilde; Christopher M Heaphy; Anirban Maitra; Alan K Meeker; Barish H Edil; Christopher L Wolfgang; Trevor A Ellison; Richard D Schulick; I Quintus Molenaar; Gerlof D Valk; Menno R Vriens; Inne H M Borel Rinkes; G Johan A Offerhaus; Ralph H Hruban; Karen E Matsukuma
Journal:  Mod Pathol       Date:  2012-05-11       Impact factor: 7.842
View more
  3 in total

Review 1.  Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.

Authors:  Günter Klöppel
Journal:  Visc Med       Date:  2017-10-16

Review 2.  Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature.

Authors:  Nikolaos Tsoukalas; Eleftherios Chatzellis; Dimitra Rontogianni; Krystallenia I Alexandraki; Georgios Boutzios; Anna Angelousi; Gregory Kaltsas
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

3.  Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer.

Authors:  Judith Buentzel; Sha Yao; Omar Elakad; Anna-Maria Lois; Jana Brünies; Julia König; Marc Hinterthaner; Bernhard C Danner; Philipp Ströbel; Alexander Emmert; Hanibal Bohnenberger
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.